Recognition and Treatment of Dysglycemia. AGS - Acute Glucose Service
Launched by JOINT AUTHORITY FOR PÄIJÄT-HÄME SOCIAL AND HEALTH CARE · Oct 10, 2017
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
The clinical trial titled "Recognition and Treatment of Dysglycemia" is studying how an Acute Glucose Service (AGS) can help manage blood sugar levels in patients undergoing knee and hip replacement surgeries. The AGS team, made up of nurse practitioners and doctors, provides care before, during, and after surgery to ensure that blood sugar levels are monitored and treated appropriately. They also focus on educating other hospital staff about managing blood sugar, which can lead to better health outcomes for patients.
To be eligible for this trial, participants need to be at least 18 years old and scheduled for elective knee or hip surgery. However, patients who cannot understand the study or provide informed consent will not be included. Participants can expect to receive personalized care and education about managing their blood sugar, which is important for their recovery and overall health. This trial aims to improve the survival rates and quality of life for patients undergoing these types of surgeries by effectively managing blood sugar levels.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients aged \> 18 years
- • Elective knee and hip arthroplasty patients
- Exclusion Criteria:
- • Patients who are incompetent to give informed consent
- • Patients who are incompetent to assess their Quality-of-Life personally
About Joint Authority For Päijät Häme Social And Health Care
The Joint Authority for Päijät-Häme Social and Health Care is a collaborative governance body dedicated to enhancing the quality and accessibility of healthcare services in the Päijät-Häme region of Finland. Comprising multiple municipalities, this authority focuses on integrating social and health services to meet the diverse needs of the population. By fostering innovative research initiatives and clinical trials, the Joint Authority aims to improve patient outcomes, advance medical knowledge, and ensure the effective delivery of comprehensive care. Its commitment to evidence-based practices and community engagement positions it as a pivotal player in the advancement of public health initiatives within the region.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lahti, , Finland
Patients applied
Trial Officials
Marianne Ylikoski, MD
Principal Investigator
Päijät Häme Central Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials